Botulinum toxin
Clinical data | |
---|---|
Trade names | Botox, Myobloc, Jeuveau, others |
Other names | BoNT, botox |
Biosimilars | abobotulinumtoxinA, daxibotulinumtoxinA, daxibotulinumtoxinA-lanm, evabotulinumtoxinA, incobotulinumtoxinA, letibotulinumtoxinA, letibotulinumtoxinA-wlbg,[1] onabotulinumtoxinA, prabotulinumtoxinA, relabotulinumtoxinA, rimabotulinumtoxinB |
AHFS/Drugs.com | |
MedlinePlus | a619021 |
License data | |
Pregnancy category | |
Intramuscular, subcutaneous, intradermal | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
ECHA InfoCard | 100.088.372 |
Chemical and physical data | |
Formula | C6760H10447N1743O2010S32 |
Molar mass | 149323.05 g·mol−1 |
(what is this?) (verify) |
Bontoxilysin | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
ExPASy | NiceZyme view | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
Gene Ontology | AmiGO / QuickGO | ||||||||
|
Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species.[19] It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis.[20] The toxin causes the disease botulism.[21] The toxin is also used commercially for medical and cosmetic purposes.[22][23] Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.[1][18]
The seven main types of botulinum toxin are named types A to G (A, B, C1, C2, D, E, F and G).[22][24] New types are occasionally found.[25][26] Types A and B are capable of causing disease in humans, and are also used commercially and medically.[27][28][29] Types C–G are less common; types E and F can cause disease in humans, while the other types cause disease in other animals.[30]
Botulinum toxins are among the most potent toxins known to science.
Medical uses
Botulinum toxin is used to treat a number of therapeutic indications, many of which are not part of the approved drug label.[23]
Muscle spasticity
Botulinum toxin is used to treat a number of disorders characterized by overactive muscle movement, including
Other muscle disorders
Strabismus, otherwise known as improper eye alignment, is caused by imbalances in the actions of muscles that rotate the eyes. This condition can sometimes be relieved by weakening a muscle that pulls too strongly, or pulls against one that has been weakened by disease or trauma. Muscles weakened by toxin injection recover from paralysis after several months, so injection might seem to need to be repeated, but muscles adapt to the lengths at which they are chronically held,[43] so that if a paralyzed muscle is stretched by its antagonist, it grows longer, while the antagonist shortens, yielding a permanent effect.[44]
In January 2014, botulinum toxin was approved by UK's Medicines and Healthcare products Regulatory Agency for treatment of restricted ankle motion due to lower-limb spasticity associated with stroke in adults.[45][46]
In July 2016, the US Food and Drug Administration (FDA) approved abobotulinumtoxinA (Dysport) for injection for the treatment of lower-limb spasticity in pediatric patients two years of age and older.[47][48] AbobotulinumtoxinA is the first and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity.[49] In the US, the FDA approves the text of the labels of prescription medicines and for which medical conditions the drug manufacturer may sell the drug. However, prescribers may freely prescribe them for any condition they wish, also known as off-label use.[50] Botulinum toxins have been used off-label for several pediatric conditions, including infantile esotropia.[51]
Excessive sweating
AbobotulinumtoxinA has been approved for the treatment of axillary hyperhidrosis, which cannot be managed by topical agents.[37][52]
Migraine
In 2010, the FDA approved
Cosmetic uses
In cosmetic applications, botulinum toxin is considered relatively safe and effective
DaxibotulinumtoxinA (Daxxify) was approved for medical use in the United States in September 2022.[18][57] It is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (wrinkles between the eyebrows).[18][57][58] DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.[18] The FDA approved daxibotulinumtoxinA based on evidence from two clinical trials (Studies GL-1 and GL-2), of 609 adults with moderate to severe glabellar lines.[57] The trials were conducted at 30 sites in the United States and Canada.[57] Both trials enrolled participants 18 to 75 years old with moderate to severe glabellar lines.[57] Participants received a single intramuscular injection of daxibotulinumtoxinA or placebo at five sites within the muscles between the eyebrows.[57] The most common side effects of daxibotulinumtoxinA are headache, drooping eyelids, and weakness of facial muscles.[57]
LetibotulinumtoxinA (Letybo) was approved for medical use in the United States in February 2024.[1][59] It is indicated to temporarily improve the appearance of moderate-to-severe glabellar lines.[1][60] The FDA approved letibotulinumtoxinA based on evidence from three clinical trials (BLESS I [NCT02677298], BLESS II [NCT02677805], and BLESS III [NCT03985982]) of 1,271 participants with moderate to severe wrinkles between the eyebrows for efficacy and safety assessment.[59] These trials were conducted at 31 sites in the United States and the European Union.[59] All three trials enrolled participants 18 to 75 years old with moderate to severe glabellar lines (wrinkles between the eyebrows).[59] Participants received a single intramuscular injection of letibotulinumtoxinA or placebo at five sites within the muscles between the eyebrows.[59] The most common side effects of letibotulinumtoxinA are headache, drooping of eyelid and brow, and twitching of eyelid.[59]
Other
Botulinum toxin is also used to treat disorders of hyperactive nerves including excessive sweating,[52] neuropathic pain,[61] and some allergy symptoms.[37] In addition to these uses, botulinum toxin is being evaluated for use in treating chronic pain.[62] Studies show that botulinum toxin may be injected into arthritic shoulder joints to reduce chronic pain and improve range of motion.[63] The use of botulinum toxin A in children with cerebral palsy is safe in the upper and lower limb muscles.[27][28]
Side effects
While botulinum toxin is generally considered safe in a clinical setting, serious side effects from its use can occur. Most commonly, botulinum toxin can be injected into the wrong muscle group or with time spread from the injection site, causing temporary paralysis of unintended muscles.[64]
Side effects from cosmetic use generally result from unintended paralysis of facial muscles. These include partial facial paralysis, muscle weakness, and trouble swallowing. Side effects are not limited to direct paralysis, however, and can also include headaches, flu-like symptoms, and allergic reactions.[65] Just as cosmetic treatments only last a number of months, paralysis side effects can have the same durations.[66] At least in some cases, these effects are reported to dissipate in the weeks after treatment.[67] Bruising at the site of injection is not a side effect of the toxin, but rather of the mode of administration, and is reported as preventable if the clinician applies pressure to the injection site; when it occurs, it is reported in specific cases to last 7–11 days.[68] When injecting the masseter muscle of the jaw, loss of muscle function can result in a loss or reduction of power to chew solid foods.[65] With continued high doses, the muscles can atrophy or lose strength; research has shown that those muscles rebuild after a break from Botox.[69]
Side effects from therapeutic use can be much more varied depending on the location of injection and the dose of toxin injected. In general, side effects from therapeutic use can be more serious than those that arise during cosmetic use. These can arise from paralysis of critical muscle groups and can include
In response to the occurrence of these side effects, in 2008, the FDA notified the public of the potential dangers of the botulinum toxin as a therapeutic. Namely, the toxin can spread to areas distant from the site of injection and paralyze unintended muscle groups, especially when used for treating muscle spasticity in children treated for cerebral palsy.[70] In 2009, the FDA announced that boxed warnings would be added to available botulinum toxin products, warning of their ability to spread from the injection site.[71][72][73][74] However, the clinical use of botulinum toxin A in cerebral palsy children has been proven to be safe with minimal side effects.[27][28] Additionally, the FDA announced name changes to several botulinum toxin products, to emphasize that the products are not interchangeable and require different doses for proper use. Botox and Botox Cosmetic were given the generic name of onabotulinumtoxinA, Myobloc as rimabotulinumtoxinB, and Dysport retained its generic name of abobotulinumtoxinA.[75][71] In conjunction with this, the FDA issued a communication to health care professionals reiterating the new drug names and the approved uses for each.[76] A similar warning was issued by Health Canada in 2009, warning that botulinum toxin products can spread to other parts of the body.[77]
Role in disease
Botulinum toxin produced by Clostridium botulinum (an anaerobic, gram-positive bacterium) is the cause of botulism.
Botulism can be difficult to diagnose, as it may appear similar to diseases such as Guillain–Barré syndrome, myasthenia gravis, and stroke. Other tests, such as brain scan and spinal fluid examination, may help to rule out other causes. If the symptoms of botulism are diagnosed early, various treatments can be administered. In an effort to remove contaminated food that remains in the gut, enemas or induced vomiting may be used.[79] For wound infections, infected material may be removed surgically.[79] Botulinum antitoxin is available and may be used to prevent the worsening of symptoms, though it will not reverse existing nerve damage. In severe cases, mechanical respiration may be used to support people with respiratory failure.[79] The nerve damage heals over time, generally over weeks to months.[80] With proper treatment, the case fatality rate for botulinum poisoning can be greatly reduced.[79]
Two preparations of botulinum antitoxins are available for treatment of botulism. Trivalent (serotypes A, B, E) botulinum
Mechanism of action
Botulinum toxin exerts its effect by cleaving key proteins required for nerve activation. First, the toxin binds specifically to presynaptic surface of
The toxin itself is released from the bacterium as a single chain, then becomes activated when cleaved by its own proteases.
The seven toxin serotypes (A–G) are traditionally separated by their antigenicity. They have different tertiary structures and sequence differences.[86][87] While the different toxin types all target members of the SNARE family, different toxin types target different SNARE family members.[82] The A, B, and E serotypes cause human botulism, with the activities of types A and B enduring longest in vivo (from several weeks to months).[86] Existing toxin types can recombine to create "hybrid" (mosaic, chimeric) types. Examples include BoNT/CD, BoNT/DC, and BoNT/FA, with the first letter indicating the light chain type and the latter indicating the heavy chain type.[88] BoNT/FA received considerable attention under the name "BoNT/H", as it was mistakenly thought it could not be neutralized by any existing antitoxin.[26]
Botulinum toxins are
History
Initial descriptions and discovery of Clostridium botulinum
One of the earliest recorded outbreaks of foodborne botulism occurred in 1793 in the village of
In 1895 Émile van Ermengem, a Belgian microbiologist, discovered what is now called Clostridium botulinum and confirmed that a toxin produced by the bacteria causes botulism.[92] On 14 December 1895, there was a large outbreak of botulism in the Belgian village of Ellezelles that occurred at a funeral where people ate pickled and smoked ham; three of them died. By examining the contaminated ham and performing autopsies on the people who died after eating it, van Ermengem isolated an anaerobic microorganism that he called Bacillus botulinus.[90] He also performed experiments on animals with ham extracts, isolated bacterial cultures, and toxins extracts from the bacteria. From these he concluded that the bacteria themselves do not cause foodborne botulism, but rather produce a toxin that causes the disease after it is ingested.[93] As a result of Kerner's and van Ermengem's research, it was thought that only contaminated meat or fish could cause botulism. This idea was refuted in 1904 when a botulism outbreak occurred in Darmstadt, Germany, because of canned white beans. In 1910, the German microbiologist J. Leuchs published a paper showing that the outbreaks in Ellezelles and Darmstadt were caused by different strains of Bacillus botulinus and that the toxins were serologically distinct.[90] In 1917, Bacillus botulinus was renamed Clostridium botulinum, as it was decided that term Bacillus should only refer to a group of aerobic microorganisms, while Clostridium would be only used to describe a group of anaerobic microorganisms.[92] In 1919, Georgina Burke used toxin-antitoxin reactions to identify two strains of Clostridium botulinum, which she designated A and B.[92]
Food canning
This section needs additional citations for verification. (August 2018) |
Over the next three decades, 1895–1925, as food canning was approaching a billion-dollar-a-year industry, botulism was becoming a public health hazard. Karl Friedrich Meyer, a Swiss-American veterinary scientist, created a center at the Hooper Foundation in San Francisco, where he developed techniques for growing the organism and extracting the toxin, and conversely, for preventing organism growth and toxin production, and inactivating the toxin by heating. The California canning industry was thereby preserved.[94]
World War II
With the outbreak of World War II, weaponization of botulinum toxin was investigated at Fort Detrick in Maryland. Carl Lamanna and James Duff[95] developed the concentration and crystallization techniques that Edward J. Schantz used to create the first clinical product. When the Army's Chemical Corps was disbanded, Schantz moved to the Food Research Institute in Wisconsin, where he manufactured toxin for experimental use and provided it to the academic community.
The mechanism of botulinum toxin action – blocking the release of the neurotransmitter acetylcholine from nerve endings – was elucidated in the mid-20th century,[96] and remains an important research topic. Nearly all toxin treatments are based on this effect in various body tissues.
Strabismus
Ophthalmologists specializing in eye muscle disorders (
After working out techniques for freeze-drying, buffering with albumin, and assuring sterility, potency, and safety, Scott applied to the FDA for investigational drug use, and began manufacturing botulinum type A neurotoxin in his San Francisco lab. He injected the first strabismus patients in 1977, reported its clinical utility in 1980,[100] and had soon trained hundreds of ophthalmologists in EMG-guided injection of the drug he named Oculinum ("eye aligner").
In 1986, Oculinum Inc, Scott's micromanufacturer and distributor of botulinum toxin, was unable to obtain product liability insurance, and could no longer supply the drug. As supplies became exhausted, people who had come to rely on periodic injections became desperate. For four months, as liability issues were resolved, American blepharospasm patients traveled to Canadian eye centers for their injections.[101]
Based on data from thousands of people collected by 240 investigators, Oculinum Inc (which was soon acquired by Allergan) received FDA approval in 1989 to market Oculinum for clinical use in the United States to treat adult strabismus and blepharospasm. Allergan then began using the trademark Botox.[102] This original approval was granted under the 1983 US Orphan Drug Act.[103]
Cosmetics
The effect of botulinum toxin type-A on reducing and eliminating forehead wrinkles was first described and published by Richard Clark, MD, a plastic surgeon from Sacramento, California. In 1987 Clark was challenged with eliminating the disfigurement caused by only the right side of the forehead muscles functioning after the left side of the forehead was paralyzed during a facelift procedure. This patient had desired to look better from her facelift, but was experiencing bizarre unilateral right forehead eyebrow elevation while the left eyebrow drooped, and she constantly demonstrated deep expressive right forehead wrinkles while the left side was perfectly smooth due to the paralysis. Clark was aware that Botulinum toxin was safely being used to treat babies with strabismus and he requested and was granted FDA approval to experiment with Botulinum toxin to paralyze the moving and wrinkling normal functioning right forehead muscles to make both sides of the forehead appear the same. This study and case report of the cosmetic use of Botulinum toxin to treat a cosmetic complication of a cosmetic surgery was the first report on the specific treatment of wrinkles and was published in the journal Plastic and Reconstructive Surgery in 1989.[104] Editors of the journal of the American Society of Plastic Surgeons have clearly stated "the first described use of the toxin in aesthetic circumstances was by Clark and Berris in 1989."[105]
Also in 1987, Jean and Alastair Carruthers, both doctors in Vancouver, British Columbia, observed that blepharospasm patients who received injections around the eyes and upper face also enjoyed diminished facial glabellar lines ("frown lines" between the eyebrows). Alastair Carruthers reported that others at the time also noticed these effects and discussed the cosmetic potential of botulinum toxin.[106] Unlike other investigators, the Carruthers did more than just talk about the possibility of using botulinum toxin cosmetically. They conducted a clinical study on otherwise normal individuals whose only concern was their eyebrow furrow. They performed their study between 1987 and 1989 and presented their results at the 1990 annual meeting of the American Society for Dermatologic Surgery. Their findings were subsequently published in 1992.[107]
Chronic pain
William J. Binder reported in 2000 that people who had cosmetic injections around the face reported relief from chronic headache.[108] This was initially thought to be an indirect effect of reduced muscle tension, but the toxin is now known to inhibit release of peripheral nociceptive neurotransmitters, suppressing the central pain processing systems responsible for migraine headache.[109][110]
Society and culture
Economics
This article needs to be updated.(October 2017) |
As of 2018[update], botulinum toxin injections are the most common cosmetic operation, with 7.4 million procedures in the United States, according to the American Society of Plastic Surgeons.[111]
The global market for botulinum toxin products, driven by their cosmetic applications, was forecast to reach $2.9 billion by 2018. The facial aesthetics market, of which they are a component, was forecast to reach $4.7 billion ($2 billion in the US) in the same timeframe.[112]
US market
In 2020, 4,401,536 botulinum toxin Type A procedures were administered.[113] In 2019 the botulinum toxin market made US$3.19 billion.[114]
Botox cost
Botox cost is generally determined by the number of units administered (avg. $10–30 per unit) or by the area ($200–1000) and depends on expertise of a physician, clinic location, number of units, and treatment complexity.[115]
Insurance
Botox for medical purposes is usually covered by insurance if deemed medically necessary by a doctor and covers a plethora of medical problems including overactive bladder (OAB), urinary incontinence due to neurologic conditions, headaches and migraines, TMJ, spasticity in adults, cervical dystonia in adults, severe axillary hyperhidrosis (or other areas of the body), blepharospasm, upper or lower limb spasticity.[116][117]
Hyperhidrosis
Botox for excessive sweating is FDA approved.[64]
Cosmetic
Standard areas for aesthetics botox injections include facial and other areas that can form fine lines and wrinkles due to every day muscle contractions and/or facial expressions such as smiling, frowning, squinting, and raising eyebrows. These areas include the glabellar region between the eyebrows, horizontal lines on the forehead, crow's feet around the eyes, and even circular bands that form around the neck secondary to platysmal hyperactivity.[118]
Bioterrorism
Botulinum toxin has been recognized as a potential agent for use in bioterrorism.[119] It can be absorbed through the eyes, mucous membranes, respiratory tract, and non-intact skin.[120] The effects of botulinum toxin are different from those of nerve agents involved insofar in that botulism symptoms develop relatively slowly (over several days), while nerve agent effects are generally much more rapid. Evidence suggests that nerve exposure (simulated by injection of atropine and pralidoxime) will increase mortality by enhancing botulinum toxin's mechanism of toxicity.[121] With regard to detection, protocols using
During the early 1980s, German and French newspapers reported that the police had raided a
Brand names
The examples and perspective in this article deal primarily with the United States and do not represent a worldwide view of the subject. (April 2017) |
Commercial forms are marketed under the brand names Botox (onabotulinumtoxinA),[14][75][125] Dysport/Azzalure (abobotulinumtoxinA),[75][126] Letybo (letibotulinumtoxinA),[1][2][127] Myobloc (rimabotulinumtoxinB),[16][75] Xeomin/Bocouture (incobotulinumtoxinA),[128] and Jeuveau (prabotulinumtoxinA).[129][56]
Botulinum toxin A is sold under the brand names Jeuveau, Botox, and Xeomin. Botulinum toxin B is sold under the brand name Myobloc.[16]
In the United States, botulinum toxin products are manufactured by a variety of companies, for both therapeutic and cosmetic use. A US supplier reported in its company materials in 2011 that it could "supply the world's requirements for 25 indications approved by Government agencies around the world" with less than one gram of raw botulinum toxin.[130] Myobloc or Neurobloc, a botulinum toxin type B product, is produced by Solstice Neurosciences, a subsidiary of US WorldMeds. AbobotulinumtoxinA), a therapeutic formulation of the type A toxin manufactured by Galderma in the United Kingdom, is licensed for the treatment of focal dystonias and certain cosmetic uses in the US and other countries.[76] LetibotulinumtoxinA (Letybo) was approved for medical use in the United States in February 2024.[1]
Besides the three primary US manufacturers, numerous other botulinum toxin producers are known. Xeomin, manufactured in Germany by Merz, is also available for both therapeutic and cosmetic use in the US.[131] Lanzhou Institute of Biological Products in China manufactures a botulinum toxin type-A product; as of 2014, it was the only botulinum toxin type-A approved in China.[131] Botulinum toxin type-A is also sold as Lantox and Prosigne on the global market.[132] Neuronox, a botulinum toxin type-A product, was introduced by Medy-Tox of South Korea in 2009.[133]
Toxin production
Botulism toxins are produced by bacteria of the genus Clostridium, namely C. botulinum, C. butyricum, C. baratii and C. argentinense,[134] which are widely distributed, including in soil and dust. Also, the bacteria can be found inside homes on floors, carpet, and countertops even after cleaning.[135] Complicating the problem is that the taxonomy for C. botulinum remains chaotic. The toxin has likely been horizontally transferred across lineages, contributing to the multi-species patten seen today.[136][137]
Food-borne botulism results, indirectly, from ingestion of food contaminated with Clostridium spores, where exposure to an anaerobic environment allows the spores to germinate, after which the bacteria can multiply and produce toxin.[135] Critically, ingestion of toxin rather than spores or vegetative bacteria causes botulism.[135] Botulism is nevertheless known to be transmitted through canned foods not cooked correctly before canning or after can opening, so is preventable.[135] Infant botulism arising from consumption of honey or any other food that can carry these spores can be prevented by eliminating these foods from diets of children less than 12 months old.[138]
Organism and toxin susceptibilities
This section needs expansion with: modern content and referencing on antibiotic susceptibilities. You can help by adding to it. (February 2015) |
Proper refrigeration at temperatures below 4.4 °C (39.9 °F) slows the growth of C. botulinum.[139] The organism is also susceptible to high salt, high oxygen, and low pH levels.[30][failed verification] The toxin itself is rapidly destroyed by heat, such as in thorough cooking.[140] The spores that produce the toxin are heat-tolerant and will survive boiling water for an extended period of time.[141]
The botulinum toxin is
Research
Blepharospasm and strabismus
University-based ophthalmologists in the US and Canada further refined the use of botulinum toxin as a therapeutic agent. By 1985, a scientific protocol of injection sites and dosage had been empirically determined for treatment of blepharospasm and strabismus.[143] Side effects in treatment of this condition were deemed to be rare, mild and treatable.[144] The beneficial effects of the injection lasted only four to six months. Thus, blepharospasm patients required re-injection two or three times a year.[145]
In 1986, Scott's micromanufacturer and distributor of Botox was no longer able to supply the drug because of an inability to obtain product liability insurance. People became desperate, as supplies of Botox were gradually consumed, forcing him to abandon people who would have been due for their next injection. For a period of four months, American blepharospasm patients had to arrange to have their injections performed by participating doctors at Canadian eye centers until the liability issues could be resolved.[101]
In December 1989, Botox was approved by the US FDA for the treatment of strabismus, blepharospasm, and hemifacial spasm in people over 12 years old.[102]
In the case of treatment of infantile esotropia in people younger than 12 years of age, several studies have yielded differing results.[51][146]
Cosmetic
The effect of botulinum toxin type-A on reducing and eliminating forehead wrinkles was first described and published by Richard Clark, MD, a plastic surgeon from Sacramento, California. In 1987 Clark was challenged with eliminating the disfigurement caused by only the right side of the forehead muscles functioning after the left side of the forehead was paralyzed during a facelift procedure. This patient had desired to look better from her facelift, but was experiencing bizarre unilateral right forehead eyebrow elevation while the left eyebrow drooped and she emoted with deep expressive right forehead wrinkles while the left side was perfectly smooth due to the paralysis. Clark was aware that botulinum toxin was safely being used to treat babies with strabismus and he requested and was granted FDA approval to experiment with botulinum toxin to paralyze the moving and wrinkling normal functioning right forehead muscles to make both sides of the forehead appear the same. This study and case report on the cosmetic use of botulinum toxin to treat a cosmetic complication of a cosmetic surgery was the first report on the specific treatment of wrinkles and was published in the journal Plastic and Reconstructive Surgery in 1989.[104] Editors of the journal of the American Society of Plastic Surgeons have clearly stated "the first described use of the toxin in aesthetic circumstances was by Clark and Berris in 1989."[105]
J. D. and J. A. Carruthers also studied and reported in 1992 the use of botulinum toxin type-A as a cosmetic treatment.[78] They conducted a study of participants whose only concern was their glabellar forehead wrinkle or furrow. Study participants were otherwise normal. Sixteen of seventeen participants available for follow-up demonstrated a cosmetic improvement. This study was reported at a meeting in 1991. The study for the treatment of
Botulinum toxin type-A has also been used in the treatment of gummy smiles;[153] the material is injected into the hyperactive muscles of upper lip, which causes a reduction in the upward movement of lip thus resulting in a smile with a less exposure of gingiva.[154] Botox is usually injected in the three lip elevator muscles that converge on the lateral side of the ala of the nose; the levator labii superioris (LLS), the levator labii superioris alaeque nasi muscle (LLSAN), and the zygomaticus minor (ZMi).[155][156]
Upper motor neuron syndrome
Botulinum toxin type-A is now a common treatment for muscles affected by the
Sialorrhea
Cervical dystonia
Botulinum toxin type-A is used to treat
Chronic migraine
Onabotulinumtoxin A (trade name Botox) received FDA approval for treatment of chronic migraines on 15 October 2010. The toxin is injected into the head and neck to treat these chronic headaches. Approval followed evidence presented to the agency from two studies funded by Allergan showing a very slight improvement in incidence of chronic migraines for those with migraines undergoing the Botox treatment.[158][159]
Since then, several randomized control trials have shown botulinum toxin type A to improve headache symptoms and quality of life when used prophylactically for participants with chronic migraine[160] who exhibit headache characteristics consistent with: pressure perceived from outside source, shorter total duration of chronic migraines (<30 years), "detoxification" of participants with coexisting chronic daily headache due to medication overuse, and no current history of other preventive headache medications.[161]
Depression
A few small trials have found benefits in people with depression.[162][163] Research is based on the facial feedback hypothesis.[164]
Premature ejaculation
The drug for the treatment of premature ejaculation has been under development since August 2013, and is in Phase II trials.[163][165]
Role in the bacterial lifecycle
Botulinum toxin serves the bacterium by paralyzing muscles in the host organism. The paralysis of the Levator ani muscles slows Defecation and hence prevents the host organism from clearing the infection through Diarrhea. When a host is infected with Clostridium botulinum and exposed to its toxin, the toxin blocks the release of acetylcholine, a neurotransmitter responsible for muscle contraction, at the neuromuscular junction. This leads to flaccid paralysis, where the affected muscles become weak or paralyzed. As a result, the host's ability to respond to the infection via increased bowl movements is compromised, which aids the bacterium in establishing and maintaining the infection.
References
- ^ a b c d e f g "Letybo (letibotulinumtoxinA-wlbg) for injection, for intramuscular use" (PDF). Archived (PDF) from the original on 2 March 2024. Retrieved 2 March 2024.
- ^ a b c "Letybo | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ a b "Nuceiva". Therapeutic Goods Administration (TGA). 10 February 2023. Retrieved 8 April 2023.
- FDA. Retrieved 22 October 2023.
- ^ "Nuceiva (PPD Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 18 March 2023. Retrieved 8 April 2023.
- ^ "Nuceiva prabotulinumtoxinA 100 Units Powder for Solution for Injection vial (381094)". Therapeutic Goods Administration (TGA). 26 January 2023. Archived from the original on 8 April 2023. Retrieved 8 April 2023.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ "Regulatory Decision Summary - Botox". Health Canada. 23 October 2014. Archived from the original on 12 June 2022. Retrieved 12 June 2022.
- ^ "Regulatory Decision Summary - Nuceiva". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 11 June 2022.
- ^ "Azzalure - Summary of Product Characteristics (SmPC)". (emc). 16 August 2022. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ "Alluzience, 200 Speywood units/ml, solution for injection - Summary of Product Characteristics (SmPC)". (emc). 2 October 2022. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ "Letybo 50 units powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 10 May 2022. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ "Xeomin 50 units powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 28 July 2022. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ a b "Botox- onabotulinumtoxina injection, powder, lyophilized, for solution". DailyMed. 30 July 2021. Archived from the original on 2 June 2022. Retrieved 12 June 2022.
- ^ "Botox Cosmetic- onabotulinumtoxina injection, powder, lyophilized, for solution". DailyMed. 9 February 2021. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ a b c "Myobloc- rimabotulinumtoxinb injection, solution". DailyMed. 22 March 2021. Archived from the original on 2 June 2022. Retrieved 12 June 2022.
- ^ "Dysport- botulinum toxin type a injection, powder, lyophilized, for solution". DailyMed. 28 February 2022. Archived from the original on 2 June 2022. Retrieved 12 June 2022.
- ^ a b c d e "Daxxify- botulinum toxin type a injection, powder, lyophilized, for solution". DailyMed. 19 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
- ^ PMID 15907915.
- S2CID 46981635.
- ^ S2CID 2855356.
- ^ S2CID 232408799.
- ^ .
- S2CID 32387953.
- ^ a b "Botulism toxin X: Time to update the textbooks, thanks to genomic sequencing". Boston Children's Hospital. 7 August 2017. Archived from the original on 14 September 2021. Retrieved 28 October 2019.
- ^ a b c "Study: Novel botulinum toxin less dangerous than thought". CIDRAP. University of Minnesota. 17 June 2015. Archived from the original on 28 October 2019. Retrieved 28 October 2019.
- ^ PMID 32224633.
- ^ PMID 31591703.
- ^ American Society of Health-System Pharmacists (27 October 2011). "OnabotulinumtoxinA (Botulinum Toxin Type A) Monograph for Professionals". drugs.com. Archived from the original on 6 September 2015. Retrieved 4 March 2015.
- ^ a b c "Fact sheets - Botulism". World Health Organization. 10 January 2018. Archived from the original on 23 March 2019. Retrieved 23 March 2019.
- PMID 31111466.
- PMID 11209178.
- PMID 17607049.
- PMID 30423587.
- ^ "Cervical dystonia - Symptoms and causes". Mayo Clinic. 28 January 2014. Archived from the original on 12 December 2018. Retrieved 14 October 2015.
- PMID 19952618.
- ^ S2CID 245177279.
- PMID 23503707.
- PMID 22251031.
- PMID 21782318.
- PMID 21412485.
- PMID 22161392.
- PMID 8014792.
- ISBN 978-0-323-14160-4. Archivedfrom the original on 28 August 2021. Retrieved 1 October 2020.
- ^ a b UK Approves New Botox Use Archived 22 February 2014 at the Wayback Machine. dddmag.com. 4 February 2014
- ^ "UK's MHRA approves Botox for treatment of ankle disability in stroke survivors". The Pharma Letter. Archived from the original on 27 July 2020. Retrieved 16 March 2020.
- ^ "FDA Approved Drug Products – Dysport". U.S. Food and Drug Administration (FDA). Archived from the original on 8 November 2016. Retrieved 7 November 2016. This article incorporates text from this source, which is in the public domain.
- PMID 26924985.
- S2CID 24857218.
- PMID 22877654.
- ^ a b Ocampo VV, Foster CS (30 May 2012). "Infantile Esotropia Treatment & Management". Medscape. Archived from the original on 28 November 2014. Retrieved 6 April 2014.
- ^ PMID 15887434.
- ^ "FDA Approves Botox to Treat Chronic Migraines". WebMD. Archived from the original on 5 May 2017. Retrieved 12 May 2017.
- PMID 31114283.
- ^ PMID 25077722.
- ^ a b Krause R (10 June 2019). "Jeuveau, The Most Affordable Wrinkle Injectable". refinery29.com. Archived from the original on 18 March 2021. Retrieved 9 July 2019.
- ^ a b c d e f g "Drug Trials Snapshot: Daxxify". U.S. Food and Drug Administration (FDA). 7 September 2022. Archived from the original on 1 February 2024. Retrieved 23 March 2024. This article incorporates text from this source, which is in the public domain.
- ^ "Revance Announces FDA Approval of Daxxify (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results" (Press release). Revance. 8 September 2022. Archived from the original on 10 September 2022. Retrieved 24 September 2022 – via Business Wire.
- ^ a b c d e f "Drug Trials Snapshots: Letybo". U.S. Food and Drug Administration (FDA). 29 February 2024. Archived from the original on 23 March 2024. Retrieved 23 March 2024. This article incorporates text from this source, which is in the public domain.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration. 29 February 2024. Archived from the original on 8 January 2024. Retrieved 2 March 2024. This article incorporates text from this source, which is in the public domain.
- S2CID 41120474.
- PMID 15598005.
- PMID 20824874.
- ^ PMID 20418969.
- ^ from the original on 23 May 2022. Retrieved 29 December 2021.
- PMID 33603602.
- PMID 33603602.
- PMID 24003345.
- from the original on 28 December 2021. Retrieved 23 November 2021.
- ^ "FDA Notifies Public of Adverse Reactions Linked to Botox Use". U.S. Food and Drug Administration (FDA). 8 February 2008. Archived from the original on 2 March 2012. Retrieved 6 May 2012. This article incorporates text from this source, which is in the public domain.
- ^ a b "FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed". Pharmaceutical Online. 4 August 2009. Archived from the original on 6 July 2019. Retrieved 16 July 2019.
- ^ "FDA Gives Update on Botulinum Toxin Safety Warnings; Established Names of Drugs Changed" (Press release). U.S. Food and Drug Administration (FDA). 3 August 2009. Archived from the original on 24 September 2015. Retrieved 18 December 2022.
- ^ "Update of Safety Review of OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc)". U.S. Food and Drug Administration (FDA). 3 August 2009. Archived from the original on 1 July 2015. Retrieved 18 December 2022.
- ^ "Follow-up to the February 8, 2008, Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)". U.S. Food and Drug Administration (FDA). 8 February 2008. Archived from the original on 2 June 2015. Retrieved 18 December 2022.
- ^ a b c d "OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) Information". U.S. Food and Drug Administration (FDA). 3 November 2018. Archived from the original on 18 December 2022. Retrieved 18 December 2022.
- ^ a b "Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc)". U.S. Food and Drug Administration (FDA). 13 September 2015. Archived from the original on 13 September 2015. Retrieved 1 September 2015. This article incorporates text from this source, which is in the public domain.
- ^ "Botox chemical may spread, Health Canada confirms". CBC News. 13 January 2009. Archived from the original on 21 February 2009.
- ^ "Kinds of Botulism". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 5 October 2016. Retrieved 4 October 2016.
- ^ a b c d "Botulism – Diagnosis and Treatment". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 5 October 2016. Retrieved 5 October 2016.
- ^ "Botulism - Diagnosis and treatment". Mayo Clinic. Archived from the original on 1 November 2023. Retrieved 1 November 2023.
- PMID 24106296.
- ^ PMID 16318699.
- PMID 20418969.
- ^ S2CID 16307223.
- ^ PMID 30388027.
- ^ PMID 21193845.
- PMID 23239346.
- ^ PMID 30347838.
- PMID 29323697.
- ^ S2CID 8190807.
- ^ S2CID 46559225.
- ^ PMID 28388718.
- PMID 22651975.
- ^ "Home Canning and Botulism". 24 June 2022. Archived from the original on 2 August 2022. Retrieved 3 August 2022.
- PMID 21026141.
- PMID 15394302.
- PMID 7099568.
- S2CID 43093912.
- PMID 4203467.
- S2CID 27341687.
- ^ a b Boffey PM (14 October 1986). "Loss Of Drug Relegates Many To Blindness Again". The New York Times. Archived from the original on 26 January 2011. Retrieved 14 July 2010.
- ^ a b "Re: Docket No. FDA-2008-P-0061" (PDF). U.S. Food and Drug Administration (FDA). 30 April 2009. Archived from the original (PDF) on 6 July 2010. Retrieved 26 July 2010. This article incorporates text from this source, which is in the public domain.
- PMID 20036435.
- ^ PMID 2748749.
- ^ PMID 14504502.
- PMID 14759577.
- ^ PMID 1740562.
- S2CID 24406607.
- PMID 22535858.
- PMID 24819339.
- ^ "New plastic surgery statistics reveal trends toward body enhancement". Plastic Surgery. 11 March 2019. Archived from the original on 12 March 2019.
- ^ Chapman L (10 May 2012). "The global botox market forecast to reach $2.9 billion by 2018". Archived from the original on 6 August 2012. Retrieved 5 October 2012.
- ^ "2020 National Plastic Surgery Statistics: Cosmetic Surgical Procedures" (PDF). American Society of Plastic Surgeons. Archived (PDF) from the original on 23 June 2021. Retrieved 22 May 2021.
- ^ "Botulinum Toxin Market". Fortune Business Insights. Archived from the original on 27 June 2021. Retrieved 22 May 2021.
- ^ "How Much Does Botox Cost". American Cosmetic Association. Archived from the original on 13 March 2023. Retrieved 13 March 2013.
- ^ "Medicare Guidelines for Botox Treatments". MedicareFAQ.com. 27 September 2021. Archived from the original on 23 May 2021. Retrieved 22 May 2021.
- ^ "BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use" (PDF). Highlights of Prescribing Information. U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 28 March 2021. Retrieved 22 May 2021.
- ^ "Botox Procedures: What is Botox & How Does it Work". The American Academy of Facial Esthetics. Archived from the original on 22 May 2021. Retrieved 22 May 2021.
- ^ Koirala J, Basnet S (14 July 2004). "Botulism, Botulinum Toxin, and Bioterrorism: Review and Update". Medscape. Cliggott Publishing. Archived from the original on 1 June 2011. Retrieved 14 July 2010.
- ^ Public Health Agency of Canada (19 April 2011). "Pathogen Safety Data Sheets: Infectious Substances – Clostridium botulinum". Archived from the original on 24 January 2022. Retrieved 24 January 2022.
- ISBN 978-0-323-39541-0. Archivedfrom the original on 11 November 2021. Retrieved 10 June 2022.
- ^ "M8 Paper" (PDF). U.S. Army. Archived (PDF) from the original on 23 October 2020. Retrieved 16 September 2020.
M8 paper is a chemically-treated, dye-impregnated paper used to detect liquid substances for the presence of V- and G-type nerve agents and H- and L-type blister agents.
- ISBN 978-0-9626523-9-4.
- ISBN 978-0-471-68678-1.
- ^ "Botulinum Toxin Type A Product Approval Information - Licensing Action 4/12/02". U.S. Food and Drug Administration (FDA). 9 February 2009. Archived from the original on 13 January 2017. Retrieved 18 December 2022.
- ^ "Drug Approval Package: Dysport (abobotulinumtoxin) NDA #125274s000". U.S. Food and Drug Administration (FDA). 17 August 2011. Archived from the original on 24 November 2019. Retrieved 23 November 2019.
- ^ "Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia". Hugel (Press release). 24 November 2022. Archived from the original on 18 December 2022. Retrieved 18 December 2022 – via PR Newswire.
- ^ "Drug Approval Package: Xeomin (incobotulinumtoxinA) Injection NDA #125360". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 27 July 2020. Retrieved 23 November 2019.
- ^ "Drug Approval Package: Jeuveau". U.S. Food and Drug Administration (FDA). 5 March 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019. This article incorporates text from this source, which is in the public domain.
- ^ "2011 Allergan Annual Report" (PDF). Allergan. Archived (PDF) from the original on 15 November 2012. Retrieved 3 May 2012. See PDF p. 7.
- ^ PMID 24587850.
- ^ "Botulinum Toxin Type A". Hugh Source (International) Limited. Archived from the original on 24 July 2008. Retrieved 14 July 2010.
- ^ Petrou I (Spring 2009). "Medy-Tox Introduces Neuronox to the Botulinum Toxin Arena" (PDF). The European Aesthetic Guide. Archived from the original (PDF) on 20 March 2013. Retrieved 9 December 2009.
- PMID 1579114.
- ^ a b c d "About Botulism". U.S. Centers for Disease Control and Prevention (CDC). 9 October 2018. Archived from the original on 27 April 2020. Retrieved 13 May 2020.
- PMID 30641949.
- PMID 19804621.
- ^ "Botulism". U.S. Centers for Disease Control and Prevention (CDC). 19 August 2019. Archived from the original on 3 August 2016. Retrieved 28 August 2019.
- ^ "Clostridium botulinum Toxin Formation" (PDF). U.S. Food and Drug Administration (FDA). 29 March 2011. p. 246. Archived (PDF) from the original on 8 February 2021. Retrieved 12 March 2023.
- PMID 5339838.
- PMID 17336071.
- PMID 19327377.
- PMID 3607594.
- PMID 2779991.
- PMID 25922620.
- S2CID 232058260.
- S2CID 29006338.
- ^ "Botulinum Toxin Type A Product Approval Information – Licensing Action 4/12/02". U.S. Food and Drug Administration (FDA). 29 October 2009. Archived from the original on 8 March 2010. Retrieved 26 July 2010. This article incorporates text from this source, which is in the public domain.
- S2CID 167319134.
- ^ "Botox Cosmetic (onabotulinumtoxinA) Product Information". Allergan. 22 January 2014. Archived from the original on 21 July 2021. Retrieved 1 March 2018.
- ^ "Allergan Receives FDA Approval for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for Botox and Botox Cosmetic (onabotulinumtoxinA)". Allergan. 24 June 2011. Archived from the original on 26 June 2011. Retrieved 26 June 2011.
- ^ "In U.S., Few Alternatives To Testing On Animals". The Washington Post. 12 April 2008. Archived from the original on 12 November 2012. Retrieved 26 June 2011.
- PMID 25654058.
- PMID 19123705.
- PMID 20529632.
- PMID 21093661.
- PMID 21242533.
- ^ "FDA approves Botox to treat chronic migraine" (Press release). U.S. Food and Drug Administration (FDA). 19 October 2010. Archived from the original on 19 October 2010. Retrieved 23 November 2019. This article incorporates text from this source, which is in the public domain.
- ^ Watkins T (15 October 2010). "FDA approves Botox as migraine preventative". CNN. Archived from the original on 27 July 2020. Retrieved 16 October 2010.
- S2CID 9621285.
- S2CID 32191932.
- S2CID 24196194.
- ^ a b "Onabotulinum toxin A - Allergan - AdisInsight". Archived from the original on 30 October 2017. Retrieved 5 September 2017.
- PMID 24345483.
- ^ Clinical trial number NCT01917006 for "An Exploratory Study of the Safety and Efficacy of Botox for the Treatment of Premature Ejaculation" at ClinicalTrials.gov
Further reading
- Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, et al. (January 2020). "DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)". Plastic and Reconstructive Surgery. 145 (1): 45–58. PMID 31609882.
- Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ (December 2021). "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". Drugs. 81 (18): 2091–2101. PMID 34787840.
External links
- Overview of all the structural information available in the PDB for UniProt: P0DPI1 (Botulinum neurotoxin type A) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P10844 (Botulinum neurotoxin type B) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: A0A0X1KH89 (Bontoxilysin A) at the PDBe-KB.
- "AbobotulinumtoxinA Injection". MedlinePlus.
- "IncobotulinumtoxinA Injection". MedlinePlus.
- "OnabotulinumtoxinA Injection". MedlinePlus.
- "PrabotulinumtoxinA-xvfs Injection". MedlinePlus.
- "RimabotulinumtoxinB Injection". MedlinePlus.